


Third Edition

Handbook of Pediatric Hematology and Oncology

Children's Hospital & Research Center Oakland

Caroline A. Hastings | Joseph C. Torkildson
Anurag K. Agrawal



WILEY Blackwell

Handbook of Pediatric Hematology and Oncology

Handbook of Pediatric Hematology and Oncology

**Children's Hospital &
Research Center Oakland**

Dr. Caroline A. Hastings

Division of Hematology, Oncology and BMT, Children's Hospital &
Research Center Oakland, Oakland, CA, USA

Dr. Joseph C. Torkildson

Division of Hematology, Oncology and BMT, Children's Hospital &
Research Center Oakland, Oakland, CA, USA

Dr. Anurag K. Agrawal

Division of Hematology, Oncology and BMT, Children's Hospital &
Research Center Oakland, Oakland, CA, USA

Third Edition

WILEY Blackwell

This edition first published 2021

© 2021 John Wiley & Sons Ltd

Wiley-Blackwell (1e, 2012)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Dr. Caroline A. Hastings, Dr. Joseph C. Torkildson, and Dr. Anurag K. Agrawal to be identified as the author(s) of this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd., The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products, visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Hastings, Caroline, 1960– author. | Torkildson, Joseph C., author. | Agrawal, Anurag K. (Anurag Kishor), author. | Children's Hospital & Research Center Oakland (Oakland, Calif.)

Title: Handbook of pediatric hematology and oncology : Children's Hospital & Research Center Oakland / Dr Caroline A. Hastings, Dr Joseph C. Torkildson, Anurag K. Agrawal.

Description: Third edition. | Hoboken, NJ : Wiley-Blackwell, 2020. | Includes bibliographical references and index.

Identifiers: LCCN 2020023659 (print) | LCCN 2020023660 (ebook) | ISBN 9781119210740 (paperback) | ISBN 9781119210764 (adobe pdf) | ISBN 9781119210757 (epub)

Subjects: MESH: Hematologic Diseases | Child | Neoplasms | Handbook
Classification: LCC RJ411 (print) | LCC RJ411 (ebook) | NLM WS 39 | DDC 618.92/994–dc23

LC record available at <https://lccn.loc.gov/2020023659>

LC ebook record available at <https://lccn.loc.gov/2020023660>

Cover Design: Wiley

Cover Images: © Billion Photos/Shutterstock

Set in 9.25/11.5pt Minion Pro by SPi Global, Pondicherry, India

On a day-to-day basis, the patients and their families continue to show us how to live gracefully in even the most unbearable of times and inspire us to endeavor for improved outcomes. Our experiences have taught us the magnitude of remembering our roles: “to cure sometimes, to relieve often, to comfort always.” (anonymous, fifteenth century)

Contents

- Preface, ix
- Acknowledgments, xi
- 1 Approach to the Anemic Child, 1
- 2 Hemolytic Anemia, 15
- 3 Sickle Cell Disease, 27
- 4 Thalassemia, 51
- 5 Transfusion Medicine, 63
- 6 Chelation Therapy, 79
- 7 Approach to the Bleeding Child, 85
- 8 Von Willebrand Disease, 95
- 9 Hemophilia, 103
- 10 Thrombophilia, 111
- 11 The Neutropenic Child, 119
- 12 Thrombocytopenia, 133
- 13 Evaluation of the Child with a Suspected Malignancy, 157
- 14 Oncologic Emergencies, 173
- 15 Acute Leukemias, 191
- 16 Central Nervous System Tumors, 211
- 17 Hodgkin and Non-Hodgkin Lymphoma, 227
- 18 Wilms Tumor, 239
- 19 Neuroblastoma, 245

- 20 Sarcomas of the Soft Tissues and Bone, 253
- 21 Germ Cell Tumors, 265
- 22 Rare Tumors of Childhood, 275
- 23 Histiocytic Disorders, 287
- 24 Hematopoietic Stem Cell Transplantation, 295
- 25 Supportive Care of the Child with Cancer, 313
- 26 Central Venous Catheters, 323
- 27 Management of Fever in the Child with Cancer, 333
- 28 Acute Pain Management in the Inpatient Setting, 347
- 29 Palliative Care, 361
- 30 Chemotherapy Basics, 377
- 31 Guide to Procedures, 393
- 32 Treatment of Chemotherapy Extravasations, 403
 - Formulary, 409
 - Index, 489

Preface

The pace of change in the field of pediatric hematology, oncology, and hematopoietic cell therapies is staggering. Molecular biology, genomics, and biochemistry have accelerated the knowledge and understanding of disease states and further highlight the complex interplay of clinical, genetic, and social factors that constantly challenge us in the rapid application of novel findings to treat patients with the goal of improved outcomes. This translation of knowledge to the unique patient before us, the true art of the physician, encompassing experience, knowledge, intuition, and understanding of the individual needs and goals of patients and families, can be overwhelming. What is needed is a practical, tested approach to analyze and address these problems to ensure timely evaluation, competent clinical care, and avoidance of pitfalls that might negatively impact the patient or future treatment options. This practical approach is achieved by spending time with patients and families

and observing the myriad variations in disease and individual nuances that are not addressed in large studies or case reports, all the while expanding foundational knowledge.

This handbook represents the work of our colleagues at Children's Hospital & Research Center Oakland toward this endeavor. The guidelines offered here have been used to instruct medical students, pediatric residents, nurses, pediatricians, and hematology/oncology fellows for over 25 years. This handbook provides clinical approaches for common problems in pediatric hematology, oncology, hematopoietic stem cell transplant, and newer cellular therapies; knowledge to organize and evaluate the care of your patients; and a framework to incorporate ever-expanding psychosocial needs, clinical studies, medical treatments, and science. All of these are essential components that encompass the care of the child with blood disorders and cancer.

Acknowledgments

We are grateful to Yoram Unguru, MD, MS, MA, for submission of the expert case and teaching guide in Chapter 29. Dr. Unguru is an attending physician in the Division of Pediatric Hematology/Oncology at the Herman & Walter Samuelson Children's Hospital at Sinai and Chairman of the Sinai Hospital Ethics Committee, as well as attending at the Johns Hopkins Berman Institute of Bioethics.

We are also extremely appreciative of patient cases submitted by Dr. Christina

Coleman Abadi, Assistant Professor of pediatrics at UCSF Benioff Children's Hospital Oakland; Dr. Cheryl Peretz, senior research fellow and clinical instructor at UCSF Benioff Children's Hospital Oakland; and Dr. Monica Davini, attending physician in the Division of Pediatric Hematology/Oncology at Banner—University Medical Center, Tucson Campus in Tucson, Arizona. These cases appear in Chapters 18, 15, and 11, respectively.

1

Approach to the Anemic Child

Anemia is the condition in which the concentration of hemoglobin or the red cell mass is reduced below normal. Anemia results in a physiological decrease in the oxygen-carrying capacity of the blood and reduced oxygen supply to the tissues. Causes of anemia are increased loss or destruction of red blood cells (RBCs) or a significant decreased rate of production. When evaluating a child with anemia, it is important to determine if the problem is isolated to one cell line (e.g., RBCs) or multiple cell lines (i.e., RBCs, white blood cells [WBCs], or platelets). When two or three cell lines are affected, it may indicate bone marrow involvement (e.g., leukemia, metastatic disease, and aplastic anemia), sequestration (i.e., hypersplenism), immune deficiency, or an immune-mediated process (e.g., hemolytic anemia and immune thrombocytopenic purpura).

Evaluation of anemia

The evaluation of anemia includes a complete medical history, family history, physical examination, and laboratory assessment (see Figure 1.1).

The diagnosis of anemia is made after reference to established normal controls for age (Table 1.1). The blood smear and red

cell indices are very helpful in the diagnosis and classification of anemia. They allow for classification by the cell size (mean corpuscular volume [MCV]), give the distribution of cell size (red cell distribution width [RDW]), and may give important diagnostic clues if specific morphological abnormalities are present (e.g., sickle cells, target cells, and spherocytes). The MCV, RDW, and reticulocyte count are helpful in the differential diagnosis of anemia. A high RDW, or anisocytosis, is seen in stress erythropoiesis and is often suggestive of iron deficiency or hemolysis. A normal or low reticulocyte count is an inappropriate response to anemia and suggests impaired red cell production. An elevated reticulocyte count suggests blood loss, hemolysis, or sequestration.

The investigation of anemia requires the following steps:

1. The medical history of the anemic child (Table 1.2), as certain historical points may provide clues as to the etiology of the anemia.
2. Detailed physical examination (Table 1.3), with particular attention to acute and chronic effects of anemia.
3. Evaluation of the complete blood count (CBC), RBC indices, and peripheral blood smear, with classification by MCV, reticulocyte count, and RBC morphology.




Figure 1.1 Diagnostic approach to the child with anemia (abbreviations: DBA, Diamond–Blackfan anemia; TEC, transient erythroblastopenia of childhood; RDW, red cell distribution width; FEP, free erythrocyte protoporphyrin; TIBC, total iron-binding capacity; G6PD, glucose-6-phosphate dehydrogenase deficiency; DAT, direct antiglobulin test).

*Refer to Table 1.1 for age-based normal values.

^Microcytosis with lead toxicity has been noted secondary to concomitant iron deficiency; see text.

Consideration should also be given to the WBC and platelet counts as well as their respective morphologies.

4. Determination of an etiology of the anemia by additional studies as needed (see Figures 1.1–1.3).

Interventions

Oral iron challenge

An oral iron challenge may be indicated in the patient with significant iron depletion, as documented by moderate-to-severe

Table 1.1 Red blood cell values at various ages.*

Age	Hemoglobin (g/dL)		MCV (fL)	
	Mean	-2 SD	Mean	-2 SD
Birth (cord blood)	16.5	13.5	108	98
1-3 d (capillary)	18.5	14.5	108	95
1 wk	17.5	13.5	107	88
2 wk	16.5	12.5	105	86
1 mo	14.0	10.0	104	85
2 mo	11.5	9.0	96	77
3-6 mo	11.5	9.5	91	74
0.5-2 y	12.0	11.0	78	70
2-6 y	12.5	11.5	81	75
6-12 y	13.5	11.5	86	77
12-18 y female	14.0	12.0	90	78
12-18 y male	14.5	13.0	88	78
18-49 y female	14.0	12.0	90	80
18-49 y male	15.5	13.5	90	80

*Compiled from the following sources: Dutcher TF. *Lab Med* 2:32-35, 1971; Koerper MA, et al. *J Pediatr* 89:580-583, 1976; Marner T. *Acta Paediatr Scand* 58:363-368, 1969; Matoth Y, et al. *Acta Paediatr Scand* 60:317-323, 1971; Moe PJ. *Acta Paediatr Scand* 54:69-80, 1965; Okuno T. *J Clin Pathol* 2:599-602, 1972; Oski F, Naiman J. *Hematological Problems in the Newborn*, 2nd ed., Philadelphia: WB Saunders, 1972, p. 11; Penttilä I, et al. *Suomen Lääkärilehti* 26:2173, 1973; and Viteri FE, et al. *Br J Haematol* 23:189-204, 1972. Cited in: Rudolph AM (ed). *Rudolph's Pediatrics*, 16th ed., Norwalk, CT: Appleton & Lange, 1977.

Abbreviation: MCV, mean corpuscular volume.

anemia and deficiencies in circulating and storage iron forms (such as an elevated total iron-binding capacity [TIBC], low serum iron, low transferrin saturation, and low ferritin). Iron absorption is impaired in certain chronic disorders (autoimmune diseases such as systemic lupus erythematosus, peptic ulcer disease, ulcerative colitis, and Crohn's disease), by certain medications (antacids and histamine-2 blockers), and by environmental factors such as lead toxicity.

Indications for an oral iron challenge include any condition in which a poor response to oral iron is being questioned, such as in: noncompliance, severe anemia secondary to dietary insufficiency (excessive milk intake), and ongoing blood loss.

Administration of an oral iron challenge is quite simple: first, draw a serum iron level; second, administer a dose of iron (3 mg/kg elemental iron) orally; third, draw another serum iron level 30-60 minutes later. The serum level is expected to increase by at least 100 mcg/dL if absorption is adequate. The oral iron challenge is a quick and easy method to assess appropriateness of oral iron to treat iron deficiency—a safer, cheaper, yet equally efficacious method of treatment as parenteral iron.

Parenteral iron therapy

Due to the potential risks of older parenteral iron preparations (specifically high-molecular-weight iron dextran), practitioners have moved to newer (and

Table 1.2 The medical history of the anemic child.

History of	Consider
Prematurity	Anemia of prematurity (EPO responsive)
Perinatal risk factors	
Maternal illness (autoimmune)	Hemolytic anemia
Drug ingestion	Impaired production
Infections (TORCH [e.g., rubella, CMV], hepatitis)	
Perinatal problems	Acute blood loss Fetal–maternal hemorrhage Iron deficiency due to the abovementioned factors or maternal iron deficiency
Ethnicity	
African-American	Hgb S, C; α - and β -thalassemia; G6PD deficiency
Mediterranean	α - and β -thalassemia; G6PD deficiency
Southeast Asian	α - and β -thalassemia; hgb E
Family history	
Gallstones, cholecystectomy	Inherited hemolytic anemia: spherocytosis, elliptocytosis
Splenectomy, jaundice at birth or with illness	Inherited enzymopathy: G6PD, pyruvate kinase deficiencies
Isoimmunization (Rh or ABO)	Hemolytic disease of newborn (also predisposed to iron deficiency)
Sex	
Male	X-linked enzymopathies (i.e., G6PD deficiency)
Early jaundice (<24 h of age)	Isoimmune, infectious
Persistent jaundice	Suggests hemolytic anemia
Diet (Usually >6 mo unless history of prematurity)	
Pica behavior	Lead toxicity, iron deficiency
Excessive milk intake	Iron deficiency
Macrobiotic/vegan diets	Vitamin B12 deficiency
Goat milk	Folic acid deficiency
Drugs	
Sulfa drugs, anticonvulsants	Hemolytic anemia (G6PD deficiency)
Chloramphenicol	Hypoplastic anemia
Low socioeconomic status	
Pica	Lead toxicity, iron deficiency
Malnutrition	
Malabsorption	Anemia of chronic disease
Environmental	Iron, vitamin B12, or folate deficiency, vitamin E or K deficiency
Liver disease	Shortened red cell survival
Renal disease	Shortened red cell survival
Decreased red cell production (\downarrow EPO)	
Infectious diseases	
Mild viral infection (acute gastroenteritis, otitis media, pharyngitis)	Transient mild decreased hgb
Sepsis (bacterial, viral, mycoplasma)	Hemolytic anemia, decreased red cell production
Parvovirus	Anemia with reticulocytopenia

Abbreviations: EPO, erythropoietin; TORCH, toxoplasmosis, other, rubella, cytomegalovirus (CMV), herpes simplex virus; G6PD, glucose-6-phosphate dehydrogenase deficiency.

Table 1.3 Physical examination of the anemic child.

System	Clinical sign or symptom	Potential underlying disorder
Skin	Pallor	Severe anemia
	Jaundice	Hemolytic anemia, acute and chronic hepatitis, aplastic anemia
	Petechiae, purpura	Autoimmune hemolytic anemia with thrombocytopenia, hemolytic uremic syndrome, bone marrow aplasia or infiltration
HEENT	Cavernous hemangioma	Microangiopathic hemolytic anemia
	Frontal bossing, prominent malar and maxillary bones	Extramedullary hematopoiesis (i.e., thalassemia major, congenital hemolytic anemia)
	Icteric sclerae	Congenital hemolytic anemia, hyperhemolytic crisis associated with infection (i.e., red cell enzyme deficiencies, red cell membrane defects, thalassemias, hemoglobinopathies), autoimmune hemolytic anemia
Chest	Angular stomatitis	Iron deficiency
	Glossitis	Vitamin B12 or iron deficiency
	Rales, gallop rhythm, tachycardia	Congestive heart failure, acute or severe anemia
Spleen	Splenomegaly	Congenital hemolytic anemia, infection, hematologic malignancies, portal hypertension
Extremities	Radial limb dysplasia	Fanconi anemia
	Spoon nails	Iron deficiency
	Triphalangeal thumbs	Red cell aplasia

perceived safer) formulations including ferric gluconate and iron sucrose. Three additional compounds have been approved, one only in Europe (iron isomaltoside) and two in the United States (ferumoxytol and ferric carboxymaltose). These newer agents have the potential benefit of total dose replacement in a very short and single infusion as compared to ferric gluconate and iron sucrose which require multiple doses. Low-molecular-weight (LMW) iron dextran is approved as a total dose infusion for adults in Europe but not the United States. Due to the smaller dose generally required

in pediatric patients, total iron replacement is feasible in 1–2 doses of LMW iron dextran and has been shown safe. Refer to the Formulary for calculation of LMW iron dextran dosing.

Severe allergic reactions can occur with iron dextran and therefore a LMW product should be preferentially utilized. A test dose (10–25 mg) should be given prior to the first dose with observation of the patient for 30–60 minutes prior to administering the remainder of the dose. A common side effect is mild to moderate arthralgias the day after drug administration, especially




Figure 1.2 Evaluation of the child with microcytic anemia (abbreviations: FEP, free erythrocyte protoporphyrin; TIBC, total iron-binding capacity; DAT, direct antiglobulin test; IBD, inflammatory bowel disease).

in patients with autoimmune disease. Acetaminophen frequently alleviates the arthralgias. Iron dextran is contraindicated in patients with rheumatoid arthritis.

Iron sucrose or ferric gluconate should be considered in patients for whom multiple doses are more feasible. Both are limited

by a maximum dose beyond which there is increased risk of adverse events. Ferumoxytol and ferric carboxymaltose have both received approval by the United States Food and Drug Administration for the treatment of iron deficiency anemia as well as renal insufficiency in adults. Both have




Figure 1.3 Approach to the full-term newborn with anemia (abbreviations: DAT, direct antiglobulin test; G6PD, glucose-6-phosphate dehydrogenase deficiency; TORCH, toxoplasmosis, other, rubella, cytomegalovirus, herpes simplex virus).

the benefit of total dose replacement given as a rapid infusion due to slow release of elemental iron. Neither is immunogenic and therefore no test dose is required. Studies

regarding utilization in pediatric patients are limited regarding appropriate per kg dosage, although the infusions appear safe and therefore will likely replace use of iron

sucrose and ferric gluconate in the future due to the convenience of single dose replacement. Refer to the Formulary for dosing parameters for these products.

Erythropoietin

Recombinant human erythropoietin (EPO) stimulates proliferation and differentiation of erythroid precursors, with an increase in heme synthesis. This increased proliferation creates an increased demand in iron availability and can result in a functional iron deficiency if not given with iron therapy.

Indications for EPO include end-stage renal disease, anemia of prematurity, anemia of chronic disease, anemia associated with treatment for AIDS, and autologous blood donation. EPO use for the treatment of chemotherapy-induced anemia remains controversial and is not routinely recommended in pediatric patients (see Chapter 25). EPO has also been used in autoimmune hemolytic anemia with low production as well as in chemotherapy-induced anemia when the family has religious beliefs that preclude transfusion. The use of EPO in this latter setting may reduce transfusion exposures but has not been validated.

The most common side effect of EPO administration is hypertension, which may be somewhat alleviated with changes in the dose and duration of administration.

Typical starting dose of EPO is 150 U/kg three times a week (IV) or subcutaneous (SC). CBCs and reticulocyte counts are checked weekly. Higher doses, and more frequent dosing, may be necessary. Response is usually seen within 1–2 weeks. Adequate iron intake (3 mg/kg/day orally or intermittent parenteral therapy) should be provided to optimize efficacy and prevent iron deficiency.

Transfusion therapy

Children with very severe anemia (i.e., hgb < 5 g/dL) may require treatment with red cell transfusion, depending on the underlying disease and baseline hemoglobin status, duration of anemia, rapidity of onset, and hemodynamic stability. The pediatric literature is scarce as to the best method of transfusing such patients. However, it appears to be common practice to give slow transfusions to children with cardiovascular compromise (i.e., gallop rhythm, pulmonary edema, excessive tachycardia, and poor perfusion) while being monitored in an ICU setting. Transfusions are given in multiple small volumes, sometimes separated by several hours, with careful monitoring of the vitals and fluid balance. For those children who have gradual onset of severe anemia, without cardiovascular compromise, continuous transfusion of 2 mL/kg/h has been shown to be safe and result in an increase in the hematocrit of 1% for each 1 mL/kg of transfused packed RBCs (based on RBC storage method). The hemoglobin should be increased to a normal value to avoid further cardiac compromise (i.e., hgb 8–12 g/dL). Again, the final endpoint may be dependent on several factors including nature of anemia, ongoing blood loss or lack of production, baseline hemoglobin, and volume to be transfused. Care should be taken to avoid unnecessary exposure to multiple blood donors by maximal use of the unit of blood, proper division of units in the blood bank, and avoidance of opening extra units for small quantities to meet a total volume. See Chapter 5 for product preparation, ordering, and premedication. A posttransfusion hemoglobin can be checked if necessary at any point after the transfusion has been completed. Waiting for “reequilibration” is anecdotal and unnecessary.

Case studies for review

1. You are seeing a 1-year-old for their well-child check in clinic. As part of routine screening, a fingerstick hemoglobin is recommended.

a. What questions in the history might help screen for anemia?

b. What about the physical examination?

Multiple questions in the history can be helpful. Dietary screening for excessive milk intake is important in addition to asking about intake of iron-rich foods such as green leafy vegetables and red meat. One should also ask about pica behavior such as eating dirt or ice and include questions regarding the age of the house to help screen for lead paint exposure and ingestion. Any sources of blood loss should also be explored including blood in the urine or stool as well as frequent gum or nose bleeding (more likely in an older child). Finally, family history should be explored regarding anemia during pregnancy, previous history of iron deficiency in siblings, and history of hemoglobinopathies.

Physical examination to search for anemia should be focused. Pallor, especially subconjunctival, perioral, and periungual, should be checked. Tachycardia, if present, would be more consistent with acute anemia rather than well-compensated chronic anemia. Splenomegaly, scleral icterus, and jaundice may point to an acute or chronic hemolytic picture.

You do the fingerstick hemoglobin in clinic and it is 10.2 g/dL. The history is not suggestive of iron deficiency and the exam is unremarkable.

c. What are the reasonable next steps?

Depending on the prevalence of iron deficiency in your population, it would be reasonable at this point to give a 1-month trial of oral iron therapy. The family should be counseled that oral iron tastes bad and

should be given with vitamin C (i.e., orange juice) and not milk to improve absorption. If there is a low likelihood of iron deficiency, a family history of thalassemia or sickle cell disease, or a suggestive newborn screen, an empiric trial of oral iron supplementation should not be performed. Similarly, if there are signs that are consistent with a hemolytic process or a significant underlying disorder, further workup should be done. In these cases, it would be correct to next perform a CBC. If there are concerns for sickle cell disease or thalassemia, it would be reasonable to also perform hemoglobin electrophoresis. If there are concerns for hemolysis, labs including reticulocyte count, total bilirubin, lactate dehydrogenase, and a direct Coombs should be performed. Finally, if there is concern for a systemic illness such as leukemia, a manual differential should be requested. Further workup for iron deficiency (ferritin, TIBC) as well as lead toxicity (lead level) could be included or deferred until the anemia is better characterized utilizing the MCV and RDW on the CBC.

2. You are seeing a 15-month-old for a routine well-child check visit. The family notes that the child has been well but appears pale to them. You ask the same questions as reviewed in case one, and the family notes a recent viral illness with no evidence of hemolysis, as there has been no history of dark-colored urine or jaundice. The dietary history is unremarkable and on review, the 1-year fingerstick hemoglobin was normal at 11.4 g/dL with a normal lead level at that time. There has been no noted diarrhea or blood loss, and the child is not on any medications. On exam, the child is pale but well appearing with a normal heart rate, respiratory rate, and blood pressure without scleral icterus or other signs of jaundice. There is no lymphadenopathy or hepatosplenomegaly. There are no petechiae or bruising.

a. What are some common diagnostic considerations?

b. What are the next laboratory steps?

Microcytic causes of anemia, notably iron deficiency anemia and secondary lead toxicity as well as thalassemia syndromes, have generally been ruled out with a history of a normal recent hemoglobin as well as a re-assuring dietary history. Congenital causes of anemia, especially Diamond–Blackfan anemia, a pure red cell aplasia, have also been ruled out with a previous normal hgb. Megaloblastic anemias are also less likely to develop in the preceding 3 months after a normal hemoglobin. Hemolytic anemia, especially warm autoimmune hemolytic anemia (AIHA), remains a possibility even without a clinical history of jaundice in patients with slow hemolytic rates. Many other diagnostic possibilities remain at this point including viral suppression secondary to infections such as parvovirus, syndromes that may have bicytopenia or pancytopenia in addition to the clinical presentation of anemia including severe aplastic anemia and acute leukemias, as well as transient erythroblastopenia of childhood (TEC). Atypical hemolytic uremic syndrome (aHUS) is an unlikely possibility, but should be in the differential diagnosis in addition to occult blood loss.

The initial laboratory workup should include labs which will help make the diagnosis and potentially treat the patient: CBC/diff, reticulocyte count, Coombs test, complete metabolic panel (CMP), LDH, type and screen, fecal occult blood, parvovirus PCR, and urinalysis (UA). CBC will help evaluate the level of anemia noted clinically as well as determine if there are more cytopenias which will help direct the differential diagnosis. The reticulocyte count will be helpful in determining if the bone marrow is responding correctly to the anemia, as it should be high with a hemolytic process and suppressed if this is post-

viral or secondary to TEC. Coombs is vital to help determine if this is an underlying warm autoimmune hemolytic anemia, noting that the Coombs will not be positive in all cases. Complete metabolic panel will look at many important aspects including renal function (to rule out aHUS), as well as bilirubin and AST which may be elevated along with the LDH if there is ongoing hemolysis. Similarly, the urinalysis will help rule out blood loss as well as hemolysis. Parvovirus PCR is not vital given the lack of clinical history, but this infection should remain in the differential diagnosis. Type and screen is important as the child may require blood transfusion depending on the level of anemia and the potential presence of hemolysis.

Lab results include the following:

Normal LDH, total, and indirect bilirubin

Normal UA

Negative direct Coombs

Normal CMP

c. What is the likely diagnosis?

The elevated reticulocyte count in the setting of a low hemoglobin should always make the practitioner first think of a hemolytic anemia, either a warm antibody or cold agglutinin. Yet, in this case, there are no other supporting laboratories for a hemolytic process. With a slow hemolytic process, it is possible that the UA, LDH, and indirect bilirubin could be normal but the direct Coombs should be helpful in the majority of warm antibody-mediated cases. In the case of a cold agglutinin (usually associated with *Mycoplasma* infection), it is possible there would be no other positive lab findings. The most likely diagnosis here is TEC in recovery phase. TEC occurs due to unclear reasons and may present with concomitant neutropenia leading to workup for acute

lymphoblastic leukemia and aplastic anemia. Patients will have a decrease in erythroid precursors in the bone marrow and therefore a decrease in peripheral reticulocytes. TEC is an indolent process and thus patients will generally present with a well-compensated but often severe normocytic anemia. Spontaneous recovery occurs with reticulocytosis, and thus TEC in the recovery phase can be mistaken for a hemolytic anemia.

Multiple choice questions

1. You are seeing a patient at their one year clinic visit and perform a finger stick hemoglobin. The hgb is 9.2 g/dl. The child has been well without any recent illnesses or significant findings on exam. What is the next best step?

- a. Empirically start iron therapy
- b. Obtain further history
- c. Check a full CBC/diff
- d. Plan to repeat in one month
- e. Perform a lead level

Explanation: It is first important to understand underlying risk factors for anemia. These could include a dietary intake of significant milk consumption which would lead to iron deficiency or a family history of thalassemia. Also it is important to ask about a bleeding history to determine if there are ongoing losses. It is important to ask about any history of jaundice or scleral icterus which would point to a hemolytic anemia as well as other inflammatory conditions which could lead to anemia of chronic disease. Choice a. would likely be correct after obtaining more history; choice c. is reasonable in cases where the history is not suggestive or the hgb does not increase with empiric iron therapy; choice d. would not be correct without other interventions; choice e. is important to do but lead toxicity itself does not lead to anemia, rather it is concomitant iron deficiency. The answer is b.

2. You are seeing a patient in the hospital admitted at two months of age for sepsis rule out secondary to high fever with associated decreased feeds and decreased urine output. The child has a urinary tract infection. A CBC is checked the hgb is 9.0 g/dl. There is no relevant family history, the mother received good prenatal care and was not anemic during pregnancy and the baby was born full term. What is the next best step?

- a. Empirically start iron therapy
- b. Plan to repeat the CBC prior to discharge
- c. Plan to repeat the CBC in 1-2 months as an outpatient
- d. Provide reassurance to the family

Explanation: Although anemia in a young infant with an underlying infection can be due to bone marrow suppression, this level of hemoglobin is normal for age. The physiologic nadir of infancy occurs around 2-3 months of age as fetal hemoglobin goes away (fetal hemoglobin lives 60-90 days as compared to hemoglobin A which lives 90-120 days). A certain level of anemia occurs prior to the bone marrow ramping up production of hemoglobin A red blood cells. Choice a. is incorrect as iron deficiency would be unlikely in this age although can occur in a very preterm infant or if the mother had severe anemia during pregnancy. Choice b. and c. are not necessary since the hb is normal for age. The answer is d.

3. You are seeing a patient in follow up. At the one year visit the finger stick hemoglobin was 9.4 g/dl. Given a nutritional history of significant milk intake you previously decided to empirically start iron therapy at a dose of 3 mg elemental iron daily and see the child today, one month later for a repeat finger stick hemoglobin. The repeat hemoglobin is now 10.2 g/dl. What is the next best step?

- a. Stop iron therapy
- b. Send a full CBC/diff

- c. Continue iron therapy and see the patient back in one month
- d. Continue iron therapy and see the patient back in 2-3 months

Explanation: Given the level of hemoglobin and nutritional history, iron deficiency is the most likely diagnosis. Reticulocyte counts should increase in 1-2 days after commencement of iron therapy and hemoglobin should rise within one week. A rise in hb in one month is reassuring that the diagnosis and treatment plan are correct. Choice a. is incorrect because it is important to continue iron therapy for 2-3 months after resolution of anemia to replete liver iron stores; as this child is still anemic it is too early to stop iron therapy. Choice b. is unnecessary at this point since the hgb is appropriately increasing with therapy but may be necessary at a later point if the anemia persists on iron therapy. Choice c. is reasonable although given the amount of time of iron therapy required to replete stores and the improvement seen to date, it is not necessary to see the patient so frequently. The answer is d.

4. You are seeing a patient in follow up. At the one year visit the finger stick hemoglobin was 9.4 g/dl. Given a nutritional history of significant milk intake you previously decided to empirically start iron therapy at a dose of 3 mg elemental iron daily and see the child today, one month later for a repeat finger stick hemoglobin. The repeat hemoglobin is now 9.2 g/dl. The mother states that the child is taking the iron well, with vitamin C, and she has decreased milk intake to 16 oz (480 ml) on average in a 24 hour period. What is the next best step?

- a. Continue iron therapy for another month and recheck hb at that time
- b. Check a CBC/diff
- c. Stop iron therapy and check a CBC/diff
- d. Stop iron therapy and check iron studies in addition to a CBC/diff

Explanation: As iron deficiency is the most likely cause of anemia, an empiric trial of iron is the correct first step. Assessing compliance with iron therapy and nutritional recommendations is very important in follow up especially if the hgb is not improved. In many cases the family is unable to give the iron well and the excessive milk intake continues. Assuming a reliable family as in the case above, it is important to now check a CBC/diff to further characterize the anemia. It would also be important to test for ongoing losses at this point with a urinalysis and fecal occult blood test. Choice a. is incorrect since iron therapy should show improvement in the hgb in 1 week and if that is not the case it is best to avoid iron overload by unnecessarily continuing iron. Choice b. though correct is not as good a choice as choice c. Choice d. is reasonable although it would be first important to check for microcytosis on the full CBC—if microcytic then it would be reasonable to test iron studies (ferritin, TIBC) in addition to checking hemoglobin electrophoresis for β -thalassemia trait given the non-responsiveness to iron therapy. The answer is c.

5. You are seeing a 15-month-old for a routine clinic visit. The family notes the child has been more tired and pale recently. There was an antecedent viral illness about one month prior but the child is now otherwise well. The child had a normal finger stick hb at one year of age, eats a varied diet, has had no noted blood loss and had no signs of jaundice. The child is pale and tachycardic but otherwise well appearing without LAD or HSM. A finger stick hemoglobin is 5.4 g/dl. Follow up CBC shows a normocytic anemia with normal WBC/diff and platelet count. The retic count is very low. What is the most likely diagnosis?

- a. Transient erythroblastopenia of childhood
- b. Iron deficiency anemia

- osteosarcoma, 260–261
- oxaliplatin, 470
- oxycodone, 352
- packed red blood cell transfusion (PRBC), 23
 - acute blood loss and nonimmune hemolytic anemia, 66
 - autoimmune hemolytic anemia, 66
 - blood transfusion guidelines, 64
 - chronically transfused patients, 66–67
 - cytomegalovirus (CMV)-negative blood, 65
 - dosing of, 67
 - exchange transfusion/erythrocytapheresis, 67
 - neonates, 65–66
 - oncology patients, 66
 - platelets and white blood cells, 65
 - severe chronic anemia, 66
- pain management, 32
 - analgesics, 347, 348
 - assessment of, 348
 - dosing of pain medication, 347
 - neonates and infants, 348
 - nonpharmacologic approaches, 354
 - oral form of medication, 347
 - pain pharmacology, 350
 - post-test, 356–357
 - preverbal/nonverbal children, 348–349
 - school-aged and older children, 349–350
 - step 1 therapy, 350–351
 - step 2 therapy, 351, 352
 - step 3 therapy, 351–353
 - step 4 therapy, 352, 354
- palliative care
 - anorexia and weight loss, 366
 - assessment
 - history, 365
 - medications, 366
 - physical examination, 365–366
 - definition, 361
 - dyspnea (*see* dyspnea)
 - end-of-life care
 - parental dissatisfaction, 363
 - symptoms, 363–365
 - fatigue, 366–367
 - gas exchange, 371
 - individualized care planning and coordination, 361–363
 - nonpharmacologic interventions, 371
 - nutritional supplementation, 366
 - supporting respiration, 369–371
 - palonosetron, 470
 - paraneoplastic syndromes, 271
 - parenteral iron therapy, 3, 5–8
 - paroxysmal nocturnal hemoglobinuria (PNH), 16
 - patient-controlled analgesia (PCA), 352
 - pazopanib, 470–471
 - pediatric antiemetics, 318, 319
 - pediatric cancers
 - abdominal mass, 168
 - adenopathy, 160, 161
 - back pain, 163
 - bicytopenia and pancytopenia, 164
 - bleeding, 165
 - bone marrow examination, 165
 - bone or joint pain, 163
 - bone pain, 164
 - cytopenias/abnormalities, 164
 - diagnosis of, 157
 - diffuse/multifocal bone pain, 163
 - excisional biopsy, 162
 - fever, 158, 159
 - headache, 159
 - incidence, 157
 - laboratory and imaging findings, 158, 162
 - lymphadenopathy, 159
 - mediastinal masses, 166
 - musculoskeletal pain, 163
 - neuroblastoma and Wilms tumor, 158, 166
 - palpable abdominal mass, 166
 - post-test, 170–172
 - splenomegaly, 162–163
 - surgical staging, 167
 - suspected leukemia, 165
 - symptoms and signs, 157, 158
 - pelvic masses, 246
 - pentamidine isethionate, 471
 - perioperative management, 43
 - perioperative transfusion, 44–45
 - peripheral blood stem cell transplant (PBSCT), 296
 - platelet surface glycoprotein, 85
 - platelet transfusions, 306
 - cryoprecipitate, 69–70
 - dosing of, 68–69
 - fresh frozen plasma, 69
 - indications, 68
 - posaconazole, 471–472
 - positron emission tomography (PET), 229
 - posterior mediastinal masses, 166

- postoperative care, 43–44
- prednisone, 472
- preoperative care, 43
- pretransplant preparative regimens, 298, 299
- priapism, 38
- prilocaine, 441–442
- primary mediastinal B-cell lymphoma (PMBCL), 232
- primordial germ cells (PGCs), 265
- procarbazine hydrochloride, 472–473
- prophylactic antibiotics, 128
- prophylaxis
 - bacterial prophylaxis, 314
 - fungal prophylaxis, 314–315
 - invasive procedures, 315
 - nutrition and dental hygiene, 313
 - prevention of, 313
 - rectal suppositories and rectal temperatures, 314
 - trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis, 314
- prothrombin deficiency, 103
- protracted fever, 340
- pyruvate kinase (PK) deficiency, 17

- radiation therapy, 215–216, 261, 280
- radiotherapy, 235
- rasburicase, 473
- recombinant factor VIIa, 85
- red blood cells (RBCs), 15
- red cell membrane disorders, 15–16
- retinoblastoma
 - clinical presentation, 276
 - diagnosis and staging, 276
 - follow-up, 277–278
 - secondary mutations, 275
 - treatment, 276–277
- retinopathy/hyphema, 42
- rhabdomyosarcoma, 253
- RhoGAM, 141
- Rho(D) immune globulin, 473–474
- Rituximab, 199
- rituximab, 143, 389, 474–475
- rivaroxaban, 475
- romiplostim, 475–476

- sacrococcygeal tumors, 267, 269
- sargramostim, 476
- severe congenital neutropenia (SCN), 123
- severe pain, 32–33

- sickle cell disease (SCD)
 - abnormal hemoglobins, 27
 - acute anemia, 40–41
 - acute chest syndrome/pneumonia, 35–38
 - alpha-thalassemia, 27
 - analgesics, 34–35
 - aplastic crisis, 41
 - avascular necrosis, 41–42
 - complementary therapies, 35
 - fever and infection in, 29–31
 - general management, 34
 - hyperbilirubinemia/gallstones, 42–43
 - inpatient, 33–34
 - mild pain, 32
 - novel agents, 45–46
 - pain management, 32
 - perioperative management, 43
 - perioperative transfusion, 44–45
 - postoperative care, 43–44
 - preoperative care, 43
 - preventive care, 28–29
 - priapism, 38
 - retinopathy/hyphema, 42
 - severe pain, 32–33
 - stroke, 38–40
 - transfusion therapy, 44
 - vaso-occlusive episodes, 27, 31–32
- single-photon emission computed tomography (SPECT), 214
- sirolimus, 476–477
- skeletal metastases, 229
- skin irritation, 327
- skin lesions, 246
- sodium thiosulfate, 477
- soft tissue hemorrhages, 105
- soft tissue sarcomas
 - clinical presentation, 254–255
 - diagnostic evaluation, 255
 - genetics, 254
 - late effects in, 263
 - pathologic diagnosis, 255–256
 - prognosis, 257–258
 - rhabdomyosarcoma, 253
 - staging and classification, 256
 - treatment, 256–257
- spinal cord compression
 - cause of, 175
 - clinical findings and evaluation, 176
 - management, 176
- splenectomy, 16, 17, 144

- splenomegaly, 122
- staging, 241
- steroids, 389–390
- storage disease, 162
- stroke, 38–40
- Stroke Prevention Trial in Sickle Cell Anemia (STOP), 39
- succimer, 477–478
- superior vena cava (SVC), 173
- superior vena cava syndrome (SVCS), 173, 228
- surgical procedures, 229
- synovial sarcoma, 253
- systemic antibiotic therapy, 328
- tacrolimus, 478
- temozolomide, 390, 478–479
- teratomas, 266
- thalassemias
 - alpha-globin chains, 51
 - alpha-thalassemias, 51–53
 - beta-globin chains, 51
 - beta-thalassemia, 53–56
 - delta beta thalassemia, 56
 - globin chain production/deletion, 51
 - HPFH, 56
 - newborn screening, 56–58
- thioguanine, 390, 479
- thiotepa, 479
- thoracic masses, 246
- thrombin, 480
- thrombin time (TT), 103
- thrombocytopenia, 123
 - acute immune thrombocytopenic purpura, 133–135
 - chronic immune thrombocytopenic purpura, 142–144
 - decreased platelet production, 149–151
 - differential diagnosis of, 134–135
 - drug-induced thrombocytopenia, 147
 - neonatal alloimmune thrombocytopenia, 144–146
 - neonatal autoimmune thrombocytopenia, 146–147
 - nonimmune thrombocytopenia, 147–149
 - post-test, 151–154
- thrombophilia
 - anticoagulation, 114–115
 - duration of therapy, 115–116
 - evaluation of, 111–112
 - management of, 113–114
 - novel anticoagulants, 116
 - prevention and treatment, 111
 - testing for, 112–113
 - thrombolysis, 114
- thyroid tumors
 - clinical presentation, 283
 - diagnosis and staging, 283–284
 - genetic predisposition, 283
 - incidence of, 282
 - treatment, 284
- tisagenlecleucel, 390–391
- tissue plasminogen activator (TPA), 329, 338
- topical anesthesia, 323
- topotecan, 391, 480–481
- total parenteral nutrition (TPN), 305, 366
- tranexamic acid, 481
- transdermal fentanyl, 352
- transfusion-associated circulatory overload, 73
- transfusion-associated graft versus-host disease, 73–74
- transfusion medicine
 - clerical errors and misidentification, 63
 - complications, 63
 - cryoprecipitate, 69–70
 - granulocyte transfusion, 70–71
 - platelet transfusions, 67–69
 - PRBC (*see* packed red blood cell transfusion (PRBC))
 - transfusion reactions, 71–74
- transfusion reactions
 - allergic transfusion reactions, 73
 - bacterial infections, 74
 - hemolytic transfusion reactions, 71–73
 - transfusion-associated circulatory overload, 73
 - transfusion-associated graft-versus-host disease, 73–74
 - transfusion-related acute lung injury, 73
- transfusion-related acute lung injury, 73
- transfusion therapy, 44
- transient myeloproliferative disorder (TMD), 199
- transplant-associated microangiopathy, 20
- transplant-associated thrombotic microangiopathy (TA-TMA), 304
- tretinoin, 481–482
- trimethoprim/sulfamethoxazole, 314, 482–483
- tumor dissemination, 267
- tumor lysis syndrome, 192
 - clinical findings and evaluation, 182
 - definition, 181–182
 - prevention and intervention, 182–184

- undifferentiated sarcoma, 253
- uridine diphosphate glucuronosyltransferase (UGT1A1), 24
- urine catecholamines, 250

- valacyclovir, 483
- valganciclovir, 483–484
- vancomycin, 339–340
- vancomycin-resistant enterococcus (VRE), 340
- vaso-occlusive episodes, 27, 31–32
- vaso-occlusive events (VOE), 355
- venlafaxine, 357
- veno-occlusive disease (VOD), 298
- venous thromboembolism, 328
- vinblastine sulfate, 484–485
- vinca alkaloids, 144
- vincristine and vinblastine, 391–392
- vincristine sulfate, 485
- vinorelbine, 485–486
- viral prophylaxis and treatment, 315–316
- visceral pain, 357
- vitamin K₁/phytonadione, 486

- Von Willebrand disease (VWD)
 - acquired von willebrand syndrome, 101
 - autosomal dominant manner, 95
 - clinical presentation, 96
 - diagnosis, 96–98
 - treatment, 98–101
 - types, 95
- von Willebrand factor (VWF), 85
- voriconazole, 486–487

- warfarin, 147
- warfarin sodium, 487–488
- white blood cell (WBC), 119
- Wilms tumor
 - clinical presentation, 240
 - evaluation of, 240
 - incidence and prevalence, 239
 - pathologic diagnosis, 240–241
 - staging, 241
 - treatment, 241–242
- Wiskott–Aldrich syndrome (WAS), 126, 150
- Wong-Baker FACES Pain Rating Scale, 350